failure following bare metal (BMS) and 1st-and 2nd-generation (gen) drug-eluting stent (DES) placement. Methods: All available material from our autopsy stent registry with duration of implant >30 days to include a total of 384 cases (mean age¼61AE13 years, 287 male) with 614 stented lesions in native coronary arteries (BMS¼266 [median, 832 days], 1st-gen DES¼285 [383 days], and 2nd-gen DES¼63 lesions [210 days]) were pathologically evaluated for the involvement of neoatherosclerosis in stent thrombosis and restenosis. Results: The prevalence of VLST (>1 year) was greater in 1st-gen DES (19%) as compared with BMS (3%) and 2nd-gen DES (0%), where in-stent plaque rupture from neoatherosclerosis accounted for 83% of VLST in BMS (5 of 6) and 15% of VLST in 1st-gen DES (5 of 33). The involvement of neoatherosclerosis in VLST increased with time; for duration of implants >3 years, all VLST in BMS (5 of 5) and 33% of VLST in 1st-gen DES (4 of 12) were attributed to in-stent rupture. VLST from in-stent rupture occurred earlier in 1st-gen DES (1434AE579 days) vs. BMS (2376AE545 days). Of the 10 lesions with in-stent rupture, only 4 (BMS¼3, 1st-gen DES¼1) had in-stent restenosis. In BMS, restenosis with underlying neoatherosclerosis was observed only >3 years, and neoatherosclerosis accounted for 38% of BMS restenosis >3 years. In contrast, both 1st-and 2nd-gen DES showed restenosis with neoatherosclerosis even 1 year. While only limited cases were available for 2nd-gen DES >1 year, 1st-gen DES showed increased involvement of neoatherosclerosis in restenosis over time, accounting for 31% of restenosis between 1 and 3 years and 78% of restenosis >3 years. Conclusions: Substantial involvement of neoatherosclerosis in late stent failure is observed in both BMS and DES, which increases over time.
Background: Noninferiority of biolimus-eluting stent (BES, Nobori) to everolimuseluting stent (EES, Xience) in clinical outcomes of drug-eluting stent (DES) implantation has been reported; however, the difference in long-term clinical and angiographic outcomes between them in the real world was little known. We aimed to compare the two-year clinical and angiographic outcomes between EES and BES. Methods: From 2010 to 2012, 4754 lesions received DES implantation: EES, 3391 lesions and BES, 1363 lesions. Midterm angiographic follow-up was scheduled at 8 months and late-term at 20 months. Target lesion revascularization (TLR) was defined as clinically or angiographically driven TLR. The TLR rate was calculated by the Kaplan-Meier methods and compared by the long-rank test. Additionally, we analyzed 2978 lesions (EES, 1153 and BES 825) after late-term follow-up, which were free from in-stent restenosis (ISR) and TLR at mid-term follow-up. ISR was defined as restenosis >50% and late catch-up phenomenon as the first ISR over one year after DES implantation. Results: Between EES and BES, there were no significant differences in the rates of midterm restenosis (7.9% vs. 8.6%, p¼0.51), late catch-up phenomenon (5.8% vs. 4.4%, p¼0.13), and TLR (6.4% vs. 7.0%, log-rank p¼0.47). Meanwhile, in a subgroup analysis, BES was significantly more effective than EES to prevent late catchup phenomenon in lesion length !30 mm and ostial lesion in the right coronary artery (see figure) .
Conclusions:
The treatment effect on late catch-up phenomenon compared between BES and EES implantations could depend on specific lesion characteristics. Background: One of the hypothesized long-term clinical benefits of Absorb BVS (Abbott Vascular, Santa Clara, CA) is plaque regression and stabilization (reduction in necrotic and lipid composition). This could also potentially mitigate in-stent neoatherosclerosis, a late adverse effect that may be responsible for recurrent acute coronary episodes. We present interim 1-year imaging evaluation (from an ongoing 4-year longitudinal study) of neointimal characteristics after coronary placement of Absorb BVS in an atherosclerotic familial hypercholesterolemic (FH) swine model. Methods: After 1 week of hypercholesterolemic diet, coronary arteries were ballooninjured. After next 20 weeks on diet, injured segments were implanted with BVS (n¼ 23) and everolimus-eluting metallic stents (EES, n¼11). Interim angiography, IVUS and OCT were performed again at 1 year. OCT analysis included previously published qualitative neointimal tissue assessment according to its pattern of backscatter and optical intensity (homogeneous, heterogeneous or layered). Results: At 1-year, all the scaffolds/stents were well apposed, widely patent and fully covered with neointima. The scaffold thickness remained unchanged from baseline. The percentage of OCT cross-sections with homogeneous pattern (previously linked to more fibrotic and less inflammatory histopathologic appearance) was significantly higher in BVS than EES (60% vs. 38%, p< 0.05). Also, the incidence of calcium around struts trended lower for BVS (13.0 % vs. 36.4 % p¼0.11) . Plaque tissue characterization (iMAP-IVUS, Boston Scientific) showed lower absolute (0.20AE0.17 mm2) and relative (6AE3%) lipid component area in BVS vs. EES (0.35AE0.24 mm2 and 8AE3%, respectively, p< 0.05). Conclusions: One year after implantation in the familial hypercholesterolemic (FH) swine model, the appearance of neointima by endovascular imaging suggests a more stable and mature composition in BVS than in the EES, yet with less calcification. This ongoing study is hoped to provide serial annual insights out to 4 years into the long-term arterial response to BVS and EES in experimental atherosclerotic setting.
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